1. INTRODUCTION
Liraglutide, a glucagon-like peptide 1 receptor (GLP-1) agonist that has
been widely used for treatment of diabetes mellitus type 2, has also
been associated with reduced risk for cardiovascular events in addition
to lowering systolic blood pressure in patients with diabetes [1].
However, increased heart rate and reduced heart rate variability have
been associated with liraglutide in patients with coronary artery
disease and diabetes [2]. However, there is no knowledge of the
effect of liraglutide on atrial fibrillation (AF) patients. In this
study, we examined the effect of liraglutide in the AF patient
population.